Recent Updates
Recently added Catalysts

AMG 529

Phase 1

Cardiovascular | Small molecule | Other |Amgen Inc.|Last Updated: Jul 5, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment48
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03170193AMG 529 First in Human StudyPHASE1 COMPLETED 48May 15, 2017Nov 17, 2017Jul 5, 20191 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Adverse Events (AEs)
From first dose up to 30 days for participants assigned to the 21 mg or 70 mg dose cohorts and up to 57 days for participants assigned to the 210 mg, 420 mg, or 700 mg dose cohorts.

Determination of the severity of adverse events was according to the following: grade 1 = mild (eg, asymptomatic or mild symptoms); grade 2 = moderate (eg, minimal intervention indicated or interferes with activity); grade 3 = severe (eg, medically significant but not immediately life-threatening, prevents daily activity, or requires treatment); grade 4 = life-threatening (ie, refers to an event in which the participant was, in the view of the investigator, at risk of death at the time of the event); and grade 5 = fatal. A serious adverse event was defined as an adverse event that met at least 1 of the following criteria: * fatal * life threatening * required in patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event.

Secondary Endpoints
Maximum Observed Concentration (Cmax) of AMG 529
Predose and at 0.5 and 1 hour postdose (IV cohort only) and 6, 12, 24, 36, 48, 72, 120, 168, 240, 366, 504, and 696 hours postdose (all participants) and additionally at days 43 and 57 for participants assigned to the 210, 420, or 700 mg dose cohorts.
Time to Maximum Observed Concentration (Tmax) of AMG 529
Predose and at 0.5 and 1 hour postdose (IV cohort only) and 6, 12, 24, 36, 48, 72, 120, 168, 240, 366, 504, and 696 hours postdose (all participants) and additionally at days 43 and 57 for participants assigned to the 210, 420, or 700 mg dose cohorts.
Area Under the Curve From Time 0 to the Last Quantifiable Concentration (AUClast) for AMG 529
Predose and at 0.5 and 1 hour postdose (IV cohort only) and 6, 12, 24, 36, 48, 72, 120, 168, 240, 366, 504, and 696 hours postdose (all participants) and additionally at days 43 and 57 for participants assigned to the 210, 420, or 700 mg dose cohorts.
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
AMG 529EXPERIMENTALParticipants received a single dose of AMG 529 at ascending dose levels by either subcutaneous or intravenous injection.
PlaceboPLACEBO_COMPARATORParticipants received a single dose of placebo matching to AMG 529 by either subcutaneous or intravenous injection.
Interventions
NameTypeDescription
AMG 529DRUGAscending single doses of AMG 529 by subcutaneous (SC) or intravenous (IV) injection
PlaceboDRUGSingle doses of matching placebo by SC or IV injection
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Healthy men and women ≥ 18 to ≤ 55 years old with no history or evidence of clinically relevant medical disorders 2. Body mass index (BMI) between 18 and 32 kg/m², inclusive, at screening 3. Women must be of non-reproductive potential as defined in protocol 4. Other inclusion...

Countries:United States
Unlock Eligibility Criteria